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Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of
primary invasive breast cancers
Aims: Small breast epithelial mucin (SBEM) is a
recently described gene product that shows promise
as a new breast biomarker. The aim was to investigate
for the ﬁrst time SBEM protein expression in a large
cohort (n = 300) of invasive breast cancers, its rela-
tionship to established clinical variables and its asso-
ciation with clinical outcome.
Methods and results: Immunohistochemical analysis
was performed on tissue microarrays consisting of
149 oestrogen receptor (ER) a) and 151 ERa+ breast
cancers. Overall, 18% of tumours were SBEM+
(n =5 3⁄ 300). However, SBEM protein was more
frequently observed in ER) (22%) than in ER+
cancers (13%; P = 0.049). A signiﬁcant association
with psoriasin ⁄ S100A7 expression (P £ 0.0001) was
observed in the entire cohort. SBEM was also positively
associated with HER-2 (P = 0.046) in ER) cancers,
and increased levels of SBEM were strongly associated
with higher tumour grade (P = 0.0015). Furthermore,
SBEM expression showed a trend towards an associa-
tion with reduced overall survival and relapse-free
survival in the ER+ cohort (P = 0.063 and P = 0.072,
respectively).
Conclusions: Our results suggest that SBEM may
identify a unique subset of breast cancers with poor
prognosis and may have future implications for ther-
apeutic management of this disease.
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Breast cancer is the most common cancer among
women and is the second leading cause of cancer death
in women in developed countries.
1,2 The 5-year
survival rate is approximately 75% for women
with locally advanced breast cancer.
2 However, if the
cancer has metastasized, the average survival time falls
to <2 years,
3,4 and at such time a very limited number
of treatment options are available for patient manage-
ment.
To date, oestrogen receptor (ER) and progesterone
receptor (PR) are the two most useful clinical markers
predicting response to hormonal therapy in both
metastatic disease and in the adjuvant setting.
5–7 More
recently, HER-2, which is overexpressed in 25% of
breast cancers and is associated with aggressive disease
and poor prognosis, has also been used in the clinical
setting, as a prognostic and predictive marker.
8 Many
other markers have been or are being investigated,
including the mucin 1 (MUC1) gene product and
related tumour antigens (CA27.29), carcinogenic
embryonic antigen, cathepsin D, gross cystic disease
ﬂuid protein ⁄ human prolactin inducible protein, mam-
maglobin and p53.
9–15 Because breast cancer encom-
passes a highly heterogeneous group of tumours, our
failure to treat or cure a given patient may result from
our inability to match the particular phenotype of the
tumour cells of the patient with the appropriate
treatment. Therefore, there is an urgent need to identify
and evaluate new breast biomarkers for monitoring
both progression and treatment of the disease. Prog-
nostically signiﬁcant clusters of breast cancers have
recently been identiﬁed by a number of investigators
reporting on gene proﬁling and tissue microarray
(TMA) analyses. The biologically distinct groups of
markers deﬁning these tumour clusters are likely to
have real clinical and prognostic ⁄ diagnostic relevance
in the near future.
16–18 Identiﬁcation of tumour mark-
ers with expression that is restricted to the mammary
epithelium would have a signiﬁcant impact not only on
reporting proliferative changes in the breast (which
may predict increased risk of breast cancer develop-
ment), but also on enhancing the detection of micro-
metastatic disease by identifying cancer cells of breast
origin in lymph nodes.
The small breast epithelial mucin (SBEM) gene, also
known as BS106 and ⁄ or B511S, was originally iden-
tiﬁed as a putative breast-speciﬁc gene.
19–22 SBEM
encodes a secreted 90 amino acids glycoprotein, which
consists of a secretion signal peptide, three tandemly
repeated octapeptide motifs (TTAAXTTA) and exhibits
characteristics of members of the mucin family.
20 Dot
blot analysis has revealed that SBEM RNA is highly
expressed in normal breast and salivary glands, but not
in other normal tissues tested, including prostate, lung,
ovary and testis.
19,20 Similarly, reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of cDNA
extracted from various cancer cell lines has revealed
consistently high levels of SBEM in breast cancer cell
lines (7 ⁄ 8), whereas none of the six non-mammary cell
lines tested was positive.
19,20 Furthermore, SBEM gene
expression, as assessed by RT-PCR, has been observed
in >90% of primary or metastatic breast cancers.
19,20
Moreover, it has recently been demonstrated that the
combined use of SBEM, cytokeratin (CK) 19, trefoil
factor-3 (p1B) and epithelial glycoprotein-2 (EGP-2)
expression allows the identiﬁcation of micrometastases
in sentinel node biopsy specimens of breast cancers,
missed by standard histological evaluation.
23
Overall, the accumulated data so far suggest that the
utility of SBEM as a new breast cancer marker may be
promising. However, with the exception of one study,
19
which was carried out on a very small cohort of breast
cancers, all studies conducted to date have examined
SBEM mRNA expression. In the latter study an
increase of SBEM protein expression in tumours versus
normal breast tissue was observed. To date, there have
been no reports in which large cohorts of selected
breast cancer cases have been evaluated for SBEM
protein expression and in which differences in SBEM
protein expression by subject characteristics have
been examined. In the present study, we have inves-
tigated SBEM protein expression by immunohisto-
chemistry (IHC) in TMAs and its association with
other established markers of prognosis, in a large
cohort of invasive breast cancers corresponding to 300
patients.
Materials and methods
breast tumour tissue microarrays
All invasive breast cancers used in the current study
were obtained from the Manitoba Breast Tumour Bank
(MBTB, Department of Pathology, University of Man-
itoba), which operates with the approval of the Faculty
of Medicine, University of Manitoba, Research Ethics
Board.
24 As described previously, all tissues are
accrued to the bank from cases at multiple centres
within Manitoba, which are collected and frozen at
)70 C immediately after surgical removal. A portion of
the frozen tissue from each case is then processed to
create matched formalin-ﬁxed parafﬁn-embedded and
frozen tissue blocks. The histopathology of all MBTB
cases has been previously assessed and entered into a
356 G P Skliris et al.
  2008 The Authors. Journal compilation   2008 Blackwell Publishing Ltd, Histopathology, 52, 355–369.computerized database to enable selection based on
composition of the tissue as well as clinicopathological
parameters. After selection, cases were re-reviewed on
haematoxylin and eosin sections by a breast pathol-
ogist (P.H.W.). ER+ and ER) TMAs were constructed
from cohorts of 246 ERa+ and 255 ERa) primary
invasive ductal breast carcinomas, respectively. In
brief, duplicate core tissue samples (0.6 mm diameter)
were taken from selected areas of maximum cellularity
for each tumour with a tissue arrayer instrument
(Beecher Instruments, Silver Spring, MD, USA). Only
tumour biopsy specimens whose ER status was deter-
mined both by ligand binding assay (LBA; ER+
>3 fmol ⁄ mg protein) and by IHC were included.
Ultimately, 300 cases provided reliable information.
In addition, a commercially available TMA (Biomax
Inc., Rockville, MD, USA; cat. No. BN08013, http://
www.biomax.us) consisting of 68 normal breast tissue
biopsy specimens was also analysed by IHC.
clinicopathological characteristics
of patient cohorts
The recommendations for tumour marker prognostic
studies (REMARK) as reported by McShane
25 were
followed as closely as possible. Case selection was based
on the following criteria: (i) a minimum patient follow-
up of 60 months; (ii) tumours had an invasive com-
ponent of >20% of the tissue section, and £10% of the
normal epithelial content; (iii) ER) status was deﬁned
by LBA criteria of £ 3 fmol ⁄ mg protein. The criteria
for interpretation of the variables were as follows:
(i) PR+ status was deﬁned as >10 fmol ⁄ mg protein by
LBA; (ii) tumour grading was consistent with the
Nottingham system (scores 3–5 = low; 6–7 = moder-
ate; and 8–9 = high); (iii) tumour size was classi-
ﬁed as either small (£20 mm) or large (>20 mm);
(iv) tumour inﬂammation was assessed on a scale from
1 to 5 and then assigned to low (score 1–3) or high
(score 4 and 5) categories. In the ER) TMA (n = 149),
patients received a variety of treatments, such as
hormonal therapy (n = 21), hormonal plus radiother-
apy (n = 6), hormonal, radiotherapy and chemother-
apy (n = 13), hormonal plus chemotherapy (n = 4),
radiotherapy alone (n = 5), radiotherapy plus chemo-
therapy (n = 43), chemotherapy alone (n = 32), sur-
gery alone (n = 21), and for four patients the treatment
regimen was unknown. In the ER+ TMA (n = 151),
patients received the following treatments: hormonal
therapy alone (n = 92), hormonal plus radiotherapy
(n = 56), hormonal and chemotherapy (n = 1) and
radiotherapy alone (n = 1), whereas one patient had
surgery alone (n = 1).
breast cancer sections
Ten pairs of matched frozen and parafﬁn-embedded
breast cancers were selected from the MBTB for
examining SBEM gene and protein expression. Serial
tissue sections obtained from these biopsy specimens
were evaluated for gene expression by both RT-PCR
and Northern blot analysis, whereas protein expression
was assessed by IHC and Western blot analysis. ER and
PR levels ranged from 2.3 to 180 fmol ⁄ mg protein and
4.5 to 105 fmol ⁄ mg protein, respectively (nine ER+
and eight PR+ breast cancers). The ages of patients
were between 58 and 78 years, and tumour size varied
from 15 to 50 mm.
rna and protein extraction
Total RNA was extracted from 20-lm frozen tissue
sections (10–20 sections ⁄ tumour) using the Trizol
 
RNA extraction protocol (Trizol
 ; Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instruc-
tions. Protein extraction was carried out as previously
described.
26 Brieﬂy, tissues were homogenized in
ice-cold homogenization buffer containing 20 mm
3-(N-morpholino)-propanesulfonic acid (pH 7.2–7.5),
60 mm b-glycerophosphate, 5 mm ethylene glycol-bis
(b-aminoethyl ether)-N,N,N¢,N¢-tetraaceticacid (pH 8.0),
5m m sodium ﬂuorate, 1 mm sodium vanadate, 1%
NP40 (all from Sigma, St Louis, MO, USA) and a mini-
protease inhibitor cocktail tablet (Boehringer Mann-
heim, Indianapolis, IN, USA) per 10-ml extraction
buffer and sonicated several times using an ultrasonic
cell disrupter (Sonics & Materials, Inc., Danbury, CT,
USA). Sonicates were centrifuged at 13 000 g for
20 min at 4 C and stored at )20 C until use. Pro-
tein concentration was determined using the Lowry
assay.
27
rt-pcr analysis
Two micrograms of total RNA was reverse-transcribed
for 1 h at 37 C as previously described.
12 A negative
control for the RT-PCR was included in which no
Moloney murine leukaemia virus (MMLV) enzyme was
added. SBEM primers consisted of a forward primer
designated SBEM-U (5¢-gatcttcaggtcaccaccatg-3¢) and
a reverse primer designated SBEM-L (5¢-gggacacactc
taccattcg-3¢). Two microlitres of each reverse tran-
scription mixture, in the presence of 20 mm Tris–HCl
(pH 8.4), 50 mm KCl, 1.5 mm MgCl2, 200 lm of each
dNTP, 200 ng of each primer and 0.5 U of Taq DNA
polymerase, was used for PCR in a ﬁnal volume
of 50 ll. Primers for glyceraldehyde-3-phosphate
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GAP-U (5¢-acccactcctccacctttg-3¢) and a reverse primer
GAP-L (5¢-ctcttgtgctcttgctggg-3¢). PCR products were
visualized with UV irradiation on a GelDoc2000 ⁄
ChemiDoc System (BioRad, Hercules, CA, USA) and
quantiﬁed by densitometry using QuantityOne software
(version 4.2; BioRad). Three independent PCRs (35
cycles; 15 s at 94 C, 15 s at 52 C and 15 s at 72 C)
were performed from each separate RT reaction and the
average of the relative signals was calculated. Brieﬂy,
SBEM signals in breast tumour no. 4 were arbitrarily
set as 1.0 and SBEM signals in all other samples were
quantiﬁed relative to tumour no. 4. This strategy was
also employed for the quantiﬁcation of the GAPDH
(control gene, Table 2). All SBEM signals were
expressed relative to the signal of tumour sample no.
4 (quantiﬁcation of SBEM mRNA levels SEM; Table 2).
northern blot analysis
Total RNA (3–15 lg) was separated by electrophoresis
on a 1% agarose gel and transferred to nylon
membranes (Schleicher & Schuell BioScience, Keene,
NH, USA) as previously described.
28 The blot was
hybridized with a 291-bp random-primed SBEM
32P-labelled probe, generated as previously described.
29
Equal loading and integrity of RNA were monitored by
ethidium bromide staining of the 28s and 18s subunits
of rRNA.
western blot analysis
Immunoblotting analysis of SBEM was performed using
an SBEM monoclonal antibody H39C51 (Dr T. Colpitts,
Abbott Laboratories), at a dilution of 1:500.
19 Equal
amounts of total protein lysates (25 lg) were extracted
and analysed by sodium dodecyl sulphate–polyacryl-
amide gel electrophoresis as previously described,
26 in
the absence or presence of a SBEM neutralizing peptide.
immunohistochemistry
Serial sections (5 lm) of the TMAs were stained with
the SBEM monoclonal antibody H218C31 at a dilution
of 1:800 (Table 1). Commercially available antibodies
were utilized for Ki67, CK5 ⁄ 6, epidermal growth factor
receptor (EGFR) and HER-2 (Table 1), while psoria-
sin ⁄ S100A7 antibody has been previously validated by
our group.
30 IHC was performed as recently reported.
31
Brieﬂy, sections were dewaxed, rehydrated and then
submitted to heat-induced antigen retrieval for 8 min
in the presence of a citrate buffer (CC1; Ventana
Medical Systems, Tucson, AZ, USA) using an auto-
mated tissue immunostainer (Discovery Staining Mod-
ule; Ventana Medical Systems). The initial dilution
quoted above was diluted further 1:3 with buffer
dispensed onto the slide with the primary antibody.
For each set of experiments, a strong SBEM+ and
an SBEM– tumour sample, as previously assessed by
RT-PCR, were included as controls. SBEM monoclonal
antibody H218C31 was further validated at the IHC
level, by pre-incubation for 4 h at 4 C with a 20-fold
excess of a SBEM peptide (69–89aa, RKDIPVLP
KWVGDLPNGRVC).
quantification and cut-off selection
Immunopositivity for SBEM protein expression in the
TMAs was assessed using semiquantitative scoring
(H-scores). H-scores were derived from a semiquanti-
tative assessment of both staining intensity (scale 0–3)
and the percentage of positive cells (0–100%), which,
when multiplied, generated a score ranging from 0
to 300. TMA immunohistochemistry was evaluated
Table 1. Details of antibodies and experimental conditions used for immunohistochemistry in the present study
Biomarker Antibody clone Supplier Dilution Incubation Method*
SBEM H218C31 Dr T. Colpitts, Abbott Laboratories 1:800 1 h at 42 C CC1
HER-2 CB11 NovocCastra, Newcastle, UK 1:50 1 h at 42 C CC1
EGFR 3C6 Ventana Systems, Tucson, AZ, USA Dispensed 30 min at 42 C Protease 1**
CK5 ⁄ 6D 5 ⁄ 16134 Zymed, San Francisco, CA, USA 1:20 1 h at 42 C CC1
KI67 MIB1 Dako, Mississauga, Canada 1:50 1 h at 42 C CC1
ERa 6F11 NovoCastra 1:50 1 hr at 42 C CC1
*Mild and standard cell conditioning, using CC1 antigen retrieval buffer (Ventana Medical Systems).
**Ventana Medical Systems using protease-1 enzyme for antigen retrieval.
SBEM, small breast epithelial mucin; EGFR, epidermal growth factor receptor; CK, cytokeratin; ER, oestrogen receptor.
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P.H.W.) and where discordance (i.e. different scores
given by different investigators) was found (30 discor-
dant cases, which were 10% of our entire cohort), cases
were re-evaluated and a consensus reached. Primary
categorical analysis was as follows: breast cancers were
considered SBEM+ with an IHC score of >0. Only
cytoplasmic reactivity was evaluated and scored. Also,
since there is at present no relevant clinical cut-off
point reported for SBEM in the literature, several cut-off
points were tested for the IHC score, equivalent to an
absence of staining, a 25th percentile and median IHC
score values. Results reported in this study were based
only on an IHC score of >0. Positivity for psoria-
sin ⁄ S100A7 (a marker that correlates with indicators
of poor prognosis) and CK5 ⁄ 6 (one of the markers of
basal phenotype) was set at >0, for Ki67 at >30
(corresponding to the median of the ER) TMA),
whereas for EGFR and HER-2, only breast cancers that
showed strong, intense membranous immunopositivity
of IHC 3+ (>30% of invasive tumour cells) were
considered positive, as reported, used and recom-
mended by other groups.
32–34
statistical analysis
Correlations were assessed by Spearman’s rank corre-
lation test (r), whereas associations between SBEM and
other clinicopathological variables were tested using
contingency methods (Fisher’s exact test). Kruskal–
Wallis test and Dunn’s method test (which compares all
pairs of columns) were taken as correction for multiple
analyses. Univariate survival analyses were performed
using the log rank test to generate Kaplan–Meier
curves. Overall survival (OS) was deﬁned as the time
from initial surgery to the date of death attributable to
breast cancer only. Relapse-free survival (RFS) was
deﬁned as the time from initial surgery to the date of
clinically documented local or distant disease recur-
rence or death attributed to breast cancer. Statistical
analyses were carried out using GraphPad Prism 4.02
version (GraphPad, San Diego, CA, USA) and SPSS 12
for windows statistics software (SPSS Inc., Chicago, IL,
USA).
Results
sbem mrna and protein expression
in primary breast cancers
As a ﬁrst step in assessing SBEM protein expression, we
examined whether an association existed between RNA
and protein levels in a small panel of 10 randomly
selected primary breast cancers. Serial sections
obtained from biopsy specimens were evaluated for
gene expression by both RT-PCR and Northern blot
analysis, whereas protein expression was assessed by
IHC and Western blot analysis.
Table 2. Correlation of
SBEM gene and protein
expression in the small
panel of 10 breast cancers
Breast
cancer
no.
Northern
blot
analysis
RT-PCRs
SBEM ⁄ GAPDH
signal ± SEM
IHC
(H-score)
Western
blot
analysis
1 ) 0.71 ± 0.13 0 )
2 + 1.52 ± 0.26 10 )
3 ) 0.70 ± 0.17 5 )
4 ) 1±0 0 )
5 + 5.8 ± 1.55 150 +
6 + 1.92 ± 0.43 0 )
7 + 3.22 ± 1.26 10 )
8 + 0.90 ± 0.36 10 )
9 ) 3.12 ± 1.50 20 )
10 + 4.56 ± 1.12 40 )
SBEM gene expression was primarily assessed by Northern blotting and secondarily by reverse
transcriptase-polymerase chain reaction (RT-PCR) analysis, whereas protein expression was
assessed by immunohistochemistry (IHC) and Western blot.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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and a single band of 291 bp corresponding to SBEM
mRNA was detected (Figure 1A). Various levels of
expression were observed (low to moderate in tumour
samples 1, 3, 4 and 9; high in all others; Figure 1A,
Table 2). Only tumours that showed the highest
expression by RT-PCR were also positive by North-
ern blot analysis. Northern blot analysis showed a
700-bp SBEM transcript, which was identiﬁed in six
out of 10 samples, with the highest level of expression
observed in tumour sample no. 5 followed by tumour
sample no. 10 (Figure 1B).
Western blot analysis revealed detectable levels of
SBEM protein only in tumour sample no. 5 (which
corresponded to the high SBEM mRNA expressor
detected by Northern blot), whereas all others were
negative (Figure 1C). In addition to the expected SBEM
band, a 25-kDa band was sometimes apparent. How-
ever, only the 17-kDa band was related to SBEM
protein, as repeatedly conﬁrmed by peptide competition
assay (data not shown).
Results from immunohistochemical analysis revealed
that seven of the 10 breast cancers were immunopos-
itive for SBEM (Table 2; Figure 2). Incubation with a
20-fold excess of the peptide abolished the SBEM signal
(Figure 3E,F). The highest protein levels were detected
in tumour no. 5, followed by tumour no. 10 (Table 2;
Figure 2). No immunoreactivity was noted in tumours
1, 4 or 6. Notably, in tumours 4, 7 and 10,
immunopositivity was observed in the surrounding
normal mammary gland (data not shown), whereas in
tumour no. 3, some normal breast ducts were SBEM+
(data not shown). Overall, SBEM protein expression
(determined by IHC) correlated with SBEM gene
expression [determined by RT-PCR (r = 0.727,
P = 0.017 two-tailed, n = 10) and also by Northern
blot analysis (tumours 5, 10, 8, 7 and 2; Table 2)].
sbem protein expression and
clinicopathological prognostic variables
in breast cancer cohort (n = 300)
Serial TMA sections were stained using IHC with
speciﬁc antibodies recognizing SBEM, Ki67, CK5 ⁄ 6,
EGFR, HER-2 and psoriasin ⁄ S100A7 (Table 1). Cyto-
plasmic reactivity was observed and scored for SBEM
and positivity was deﬁned as an IHC score of >0. From
our studies, data on SBEM protein expression in 300
breast cases were obtained, but for the analysis of some
of the other markers the numbers of cases analysed are
slightly lower due to missing tumour cores on the
TMAs, or unavailable data for analysis (Table 3). In
this combined cohort of ER+ and ER) invasive breast
cancers, 18% of tumours were positive for SBEM
(n =5 3⁄ 300). Using categorical analysis (i.e. SBEM
deﬁned as positive or negative), SBEM was strongly
positively associated with psoriasin ⁄ S100A7 [Fisher’s
exact test, P £ 0.0001, n = 280, odds ratio (OR)
6.77, 95% conﬁdence interval (CI) 3.2, 14; Table 3],
a marker that correlates with other indicators of
poor prognosis,
30,35,36 and negatively associated with
Ki67, a marker of proliferation (Fisher’s exact test,
P = 0.009, n = 230, OR 0.356, 95% CI 0.16, 0.78),
and ERa (Fisher’s exact test, P = 0.049, n = 300, OR
0.536, 95% CI 0.29, 0.98). No other statistically
signiﬁcant associations between SBEM and established
prognostic factors such as tumour size, axillary lymph
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Figure 1. SBEM RNA and protein expression in a small panel of 10
human breast cancers. RNA and protein were extracted from breast
cancers (n = 10) as described in Materials and Methods. Numbers
(1–10) represent individual tumours. A, RT-PCR analysis. ‘N’ is a
negative RT-PCR, i.e. reverse transcription performed minus MMLV
enzyme, and ‘B’ is a PCR negative control. Lane M, PhiX174 RF
DNA ⁄ Hae III DNA ladder. B, Northern blot analysis. Breast cancers
were analysed as described in Materials and methods. Fifteen
micrograms of total RNA from tumours 1–7, three from tumour
no. 8, 10 lg from no. 9 and 6 lg from no. 10 were separated on
agarose gels and hybridized using SBEM
32P-labelled probes. Loading
controls are provided with 18s and 28s RNA bands on the bottom
panel M, ladder. C, Western blot analysis. Total proteins (25 lg) were
analysed by sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis using the SBEM H39C51 monoclonal antibody. M = ladder.
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Figure 2. Immunohistochemical analysis of SBEM expression in the small panel of 10 human breast cancers. Immunohistochemistry was
performed as described in Materials and Methods. Patient ⁄ sample identiﬁcation is indicated on top left of each picture, and the corresponding
H-score for IHC is presented on the bottom right corner. H-scores were derived from semiquantitative assessment of both staining intensity
(scale 0–3) and the percentage of positive cells (0–100%) and, when multiplied, generate a score ranging from 0 to 300. Bar = 50 lm.
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(Table 3). Interestingly, even though no association
existed between overall survival and SBEM expression
(Figure 4A), a trend toward signiﬁcance was observed
for those breast cancers that exhibited high levels of
SBEM positivity and a shorter time to disease progres-
sion, compared with those that were SBEM) [low
levels, P = 0.057, n = 300, hazard ratio (HR) 0.65,
95% CI of ratio 0.37, 1.04; Figure 4B]. This trend,
along with the strong association observed with
psoriasin expression, prompted us to examine further
the relationship between SBEM protein expression and
the ER status of the tumours.
sbem protein expression, clinicopathological
prognostic variables and survival in
er) breast cancers
In the ER) breast cancers analysed, only 22% of
tumours were SBEM+ (n =3 3⁄ 149). There was a
positive and statistically signiﬁcant correlation between
SBEM and psoriasin ⁄ S100A7 expression (Spearman
coefﬁcient, r = 0.44, P < 0.0001, n = 146, 95% CI
0.29, 0.56). A signiﬁcant inverse correlation with
Ki67 (Spearman coefﬁcient, r = )0.39, P < 0.0001,
n = 148, 95% CI )0.52, )0.23) and CK5 ⁄ 6, a basal
epithelial phenotype marker, was also observed (r =
)0.34, P < 0.0001, n = 130, 95% CI )0.48, )0.17).
Univariate analysis showed that SBEM was signiﬁ-
cantly associated with psoriasin ⁄ S100A7 (Fisher’s
exact test, P=< 0.0001, n = 146, OR 14.48, 95%
CI 3.3, 63.5; Table 4) and less signiﬁcantly with HER-2
(Fisher’s exact test, P = 0.046, n = 135, OR 2.39, 95%
CI 1.04, 5.48; Table 4). In the same cohort, SBEM was
negatively associated with Ki67 and CK5 ⁄ 6, respec-
tively (Fisher’s exact test, P=< 0.0001, n = 148, OR
0.232, 95% CI 0.098, 0.545; and P=< 0.0001, n =
130, OR 0.147, 95% CI 0.057, 0.381; Table 4),
whereas lack of SBEM expression was associated with
higher tumour grade (Fisher’s exact test, P = 0.0015,
n = 139). No other statistically signiﬁcant associations
between SBEM and established prognostic factors such
as tumour size, axillary lymph node status and PR were
observed (Table 4). Furthermore, no difference in
disease outcome (OS and RFS) was found between
low and high SBEM expression (Figure 4C,D).
A  B  C 
F  E  D 
Figure 3. SBEM expression, determined by immunohistochemistry in ER+ and ER) tissue microarrays. A, ER+ cancer stained with the
SBEM monoclonal antibody (H218C31) showing no expression (H-score of 0). B, ER+ tumour showing low expression (H-score of 30).
C, ER+ breast cancer showing medium expression (H-score of 60). D, ER+ tumour showing high expression (H-score of 225). E,E R ) breast
cancer (ER and PR levels of 2.3 and 8.9 fmol ⁄ mg protein, respectively) immunoreactive for the H218C31 SBEM-speciﬁc antibody showing
high expression. F, Serial section of the ER) breast cancer, where the primary antibody was incubated with ·20-fold excess SBEM peptide
and abolished the speciﬁc stain.
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prognostic variables and survival in
er+ breast cancers
In the ER+ breast cancers, 13% of tumours (n =
20 ⁄ 151) were immunopositive for SBEM (Figure 3A–D).
SBEM was signiﬁcantly correlated and associated with
psoriasin ⁄ S100A7, respectively (Spearman’s coefﬁ-
cient, r = 0.21, P = 0.015, n = 132, 95% CI 0.036,
0.373; and Fisher’s exact test, P = 0.016, n = 134, OR
4.053, 95% CI 1.34, 12.21; Table 5). No other
associations between SBEM and established prognostic
Table 3. Distribution of SBEM+ and SBEM) cases within the cohort of 300 patients
Prognostic factor ⁄
characteristics
Number
(n) Subgroup cut-offs SBEM+ % SBEM) % P-value
EGFR 248 + 6 14 23 11 0.61
) 38 86 181 89
HER-2 231 + 16 37 48 32 0.13
) 27 67 140 68
CK5 ⁄ 6 272 + 16 33 100 45 0.20
) 32 67 124 55
Ki67 230 x ‡ 30 9 20 78 42 0.009
x < 30 35 80 108 58
S100A7 280 + 37 77 77 33 <0.0001
) 11 23 155 67
PR (LBA) 300 x ‡ 10 fmol ⁄ mg 32 60 152 62 0.88
x < 10 fmol ⁄ mg 21 40 95 38
Node 300 + 17 32 55 22 0.16
) 36 68 192 78
Age 300 x > 50 45 85 185 75 0.15
x £ 50 8 15 62 25
Grade 290 Low (3–5) 8 16 33 13 0.70
Mod (6–7) 28 55 121 51
High (8–9) 15 29 85 36
Size 300 >20 mm 35 66 172 70 0.62
£ 20 mm 18 34 75 30
ERa (IHC) 300 + 20 38 131 53 0.049
) 33 62 116 47
For each characteristic, clinical and pathological (see Materials and Methods), the total number of cases is given (n). P-values
have been calculated following Fisher’s exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was
performed with GraphPad Prism 4.02 software (San Diego, CA, USA), and statistically signiﬁcant values are in bold.
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay; ER, oestrogen
receptor.
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(Table 5). However, using the log rank test to generate
Kaplan–Meier curves, an interesting trend toward
signiﬁcance was observed in disease outcome (OS and
RFS), with patients with higher SBEM levels being
associated with worse survival and a shorter time to
progression (P = 0.063, HR 0.461, 95% CI of ratio
0.117, 1.060; and P = 0.072, HR 0.522, 95% CI of
ratio 0.172, 1.078, respectively; Figure 4E,F).
sbem protein expression in normal breast
tissue
IHC was also performed on a TMA consisting of 68
normal tissues (Biomax; cat. No. BN08013). Moderate
to strong immunoreactivity for SBEM was detected in
nine normal tissues (three breast ducts, six ﬁbro-fatty
tissues) and SBEM expression was calculated at 13%
(9 ⁄ 68 cases). Three malignant breast biopsy speci-
mens, included as markers for orientation purposes in
the TMA, showed no speciﬁc SBEM reactivity (0 ⁄ 3). A
highly positive SBEM breast cancer sample and a
SBEM) one, previously assessed by RT-PCR, were used
as controls, for IHC analysis.
Discussion
Most data on SBEM thus far have been accumulated
from gene expression studies, whereas SBEM protein
expression in human breast cancers has not been
explored. As a ﬁrst step in addressing SBEM protein
expression in breast cancer, we examined the relation-
ship between gene and protein expression. As expected,
differences were observed when using techniques with
known different levels of sensitivity. For example, when
all samples were positive using RT-PCR, SBEM protein
was detected in only one tumour by Western blot
analysis. This underscores the critical importance of
setting standards and references to be used in the
assessment of expression of a speciﬁc biomarker
for clinical management purposes. A signiﬁcant cor-
relation was found between results from protein
assessment by IHC and RNA measurement by semi-
quantitative RT-PCR. This ﬁnding was surprising, as
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Figure 4. Kaplan–Meier graphs
for overall survival and relapse
free survival-time to progres-
sion for SBEM expression in the
entire breast cancer cohort
(A,B), ER a) (C,D) and ERa+
cancers (E,F). Symbols on the
graph lines represent censored
data, P-values are given for log
rank tests. A (top left), n = 300;
low SBEM events = 80, high
SBEM events = 23; B (top
right), n = 300; low SBEM
events = 95, high SBEM
events = 26; C (left), n = 149;
low SBEM events = 57, high
SBEM events = 16; D (right),
n = 149; low SBEM
events = 55, high SBEM
events = 17; E (bottom left),
n = 151; low SBEM
events = 23, high SBEM
events = 7; F (bottom right),
n = 151; low SBEM
events = 40, high SBEM
events = 9.
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positivity (ER, for example), we were not expecting
statistical signiﬁcance when comparing with a semi-
quantitative assay performed on such a small cohort
(n = 10). This suggests that a strong association exists
between SBEM RNA and protein expression. It also
suggests that an even better estimation of the expres-
sion of this gene might be performed with the more
quantitative real-time PCR. If SBEM is to be used as
a clinical biomarker, the possibility of accurately
measuring its levels from a tiny amount of tissue
(biopsy specimen) is another major advantage to be
considered.
The ﬁndings presented here include the largest
number of breast cancers to date to examine SBEM
protein expression. In a combined cohort of 300 ER+
and ER) invasive breast cancers, it was found that
18% of cancers were positive for SBEM. SBEM was also
found to be highly associated with psoriasin ⁄ S100A7,
a member of the S100 family of genes. Psoria-
sin ⁄ S100A7 is known to correlate with indicators of
poor prognosis, speciﬁcally in ERa) breast cancers, and
Table 4. Distribution of SBEM+ and SBEM) cases within the ER) cohort (n = 149)
Prognostic factor ⁄
characteristics
Number
(n) Subgroup cut-offs SBEM+ % SBEM) % P-value
EGFR 116 + 5 20 23 25 0.79
) 20 80 68 75
HER-2 135 + 14 42 24 23 0.046
) 19 58 78 77
CK5 ⁄ 6 130 + 7 24 69 68 <0.0001
) 22 76 32 32
Ki67 148 x ‡ 30 9 27 71 62 <0.0001
x < 30 24 73 44 38
S100A7 146 + 30 94 58 51 <0.0001
) 2 6 56 49
PR (LBA) 149 x ‡ 10 fmol ⁄ mg 13 39 36 31 0.40
x < 10 fmol ⁄ mg 20 61 80 69
Node 149 + 17 52 55 47 0.70
) 16 48 61 53
Age 149 x > 50 25 76 69 59 0.10
x £ 50 8 24 47 41
Grade 139 Low (3–5) 3 10 3 3 0.015
Mod (6–7) 15 48 32 30
High (8–9) 13 42 73 67
Size 149 >20 mm 23 70 82 71 1.0
£ 20 mm 10 30 34 29
For each clinical and pathological characteristic (see Materials and Methods), the total number of cases is given (n). P-values
have been calculated following Fisher’s exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was
performed with GraphPad Prism 4.02 software (San Diego, CA, USA), and statistically signiﬁcant values are in bold.
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay.
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clinical outcome.
30,35,36 To investigate SBEM protein
expression further in separate subgroups, we divided
the patient cohort according to ER status (as deter-
mined by both the ligand binding assay and IHC). In
the ERa) TMA, which represents a more aggressive
group of breast cancers, SBEM protein was detected
in 22% of breast cancers. Univariate analysis showed
that SBEM was strongly associated with psoriasin ⁄
S100A7 and less so with HER-2, the latter being well
documented to confer poor prognosis in breast
cancer patients. Interestingly, a signiﬁcant association
between HER-2 determined by IHC and increasing
amounts of SBEM mRNA (P = 0.003) has also been
reported by others.
37 These results suggest that SBEM,
like psoriasin ⁄ S100A7 and HER-2, may also be asso-
ciated with poor prognosis, an observation which is
consistent with our previous ﬁndings that SBEM mRNA
expression was higher in node-positive tumours.
20
Interestingly, in the ER-positive ⁄ node-negative cohort,
SBEM expression was also signiﬁcantly associated with
psoriasin ⁄ S100A7, and perhaps identiﬁes, within a
Table 5. Distribution of SBEM+ and SBEM) cases within the ER-positive cohort (n = 151)
Prognostic factor ⁄
characteristics
Number
(n) Subgroup cut-offs SBEM+ % SBEM) % P-value
EGFR 132 + 1 5 0 0 0.14
) 18 95 113 100
HER-2 96 + 2 20 24 28 0.72
) 88 0 6 2 7 2
CK5 ⁄ 6 142 + 9 47 31 25 0.06
) 10 53 92 75
Ki67 82 x ‡ 30 0 0 7 10 0.58
x < 30 11 100 64 90
S100A7 134 + 7 44 19 16 0.016
) 95 6 9 9 8 4
PR (LBA) 151 x ‡ 10 fmol ⁄ mg 19 95 116 89 0.70
x < 10 fmol ⁄ mg 1 5 15 11
Node 151 + 0 0 0 0 1.0
) 20 100 131 100
Age 151 x > 50 20 100 116 89 0.22
x £ 50 0 0 15 11
Grade 151 Low (3–5) 5 25 30 23 0.96
Mod (6–7) 13 65 89 68
High (8–9) 2 10 12 9
Size 151 >2 12 60 90 69 0.45
£ 2 8 40 41 31
For each clinical and pathological characteristic (Materials and Methods), the total number of cases is given (n). P-values have
been calculated following Fisher’s exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was
performed using the GraphPad Prism software version 4.02 (San Diego, CA, USA), and statistically signiﬁcant values are in bold.
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay.
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very good prognosis, a minority of patients more likely
to experience recurrence of disease. This is emphasized
by the fact that strong trends were observed toward
both a lower survival rate and a higher recurrence of
the disease in SBEM+ patients. SBEM protein, however,
was more frequently expressed in ER) breast cancers,
consistent with its positive association with psoriasin ⁄
S100A7 and HER-2. Furthermore, it is interesting that
a SBEM correlation exists with Ki67, but not with
tumour grade. However, correlation with proliferation
index but not with grade could arise from lack of
association or competing association with the other
components of tumour grade (which was based on the
Nottingham grading score, in which the grade reﬂects
nuclear morphology and tubular differentiation, as well
as proliferation rate). Further pathological analysis is
required to explore this aspect.
Because of the heterogeneous nature of breast
cancers, it is unlikely that any single tumour marker
would be sufﬁcient for breast cancer diagnosis or
detection of metastasis. Indeed, an increasing number
of reports have suggested that the use of multiple
markers could indeed improve the likelihood of detect-
ing tumour cells across the population.
23,38,39 Identi-
ﬁcation of a new subset of patients using SBEM protein
detection would be likely to enhance the potency of
such a multimarker set. In line with such a multimar-
ker strategy to disease management, we have previ-
ously shown that both SBEM and mammaglobin gene
expression correlate positively with axillary lymph
node metastasis.
20 SBEM has also been included in a
list of markers (18 in total) currently used for the
detection of disseminated tumour cells, and their
signiﬁcance and limitations have been reviewed and
discussed.
22 In addition, a marker set containing CK19,
p1B, EGP2 and SBEM has been reported to facilitate the
discrimination between negative and positive lymph
nodes in breast cancer patients.
23 Recently, SBEM
(BS106) gene expression has also been investigated
with real-time PCR in a series of breast cancers, lymph
nodes from cancer and non-cancer patients and normal
breast tissues.
37 SBEM was highly expressed in all but
one breast cancers and in all normal breast tissues. The
authors concluded that SBEM added to the potential
utility of other markers in breast cancer, such as
mammaglobin and CK19.
37
The TMAs used in this study were constructed with
duplicate cores (0.6 mm) derived from each tumour
sample. Our results have shown some heterogeneity in
SBEM staining. Furthermore, it may be a matter of
concern whether two cores are entirely representative
of gene expression in a large tumour sample, as they
could result in both over- and underscoring of protein
expression in the TMA. However, although we cannot
entirely exclude this possibility, previous studies by
others have shown that with use of the standard breast
cancer prognostic markers (ER, PR and HER-2), two
cores are sufﬁcient and have resulted in >95% accu-
racy.
40–42 Similarly, two cores have also been reported
to provide a high level of accuracy in the TMA analysis
of other cancers, such as metastatic prostate and
ovarian cancer.
43,44
Overall, SBEM expression was observed in 22% of
ERa) and 13% of ERa+ breast cancers. No statistically
signiﬁcant association between SBEM expression and
clinical outcome was observed. However, in ER+ breast
cancers a deﬁnite trend toward signiﬁcance between
SBEM protein levels and disease outcome of patients
was observed, suggesting that SBEM may be associated
with worse survival and shorter time to progression in
this speciﬁc subgroup. In ER) cancers, SBEM protein
expression was highly associated with some markers of
poor prognosis. We believe further analyses are needed,
using real-time RT-PCR, to reﬁne our assessment of
SBEM expression in breast cancers. Altogether, these
results suggest that SBEM may identify a unique subset
of breast cancers and may have future implications for
therapeutic management of the disease.
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